Cargando…
Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non‐histaminergic angioedema
Autores principales: | Alizadeh Aghdam, Mehran, Hofman, Zonne L. M., Meertens, Michelle, Lebens, Ans, Hack, C. Erik, Knulst, André C., Maas, Coen, Röckmann, Heike |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084080/ https://www.ncbi.nlm.nih.gov/pubmed/35837765 http://dx.doi.org/10.1111/all.15437 |
Ejemplares similares
-
High occurrence of antihistamine resistance in patients with recurrent idiopathic angioedema
por: Hofman, Zonne L. M., et al.
Publicado: (2019) -
Bradykinin: Inflammatory Product of the Coagulation System
por: Hofman, Zonne, et al.
Publicado: (2016) -
Idiopathic non-histaminergic acquired angioedema: a case series and discussion of published clinical trials
por: Bucher, Martin Christian, et al.
Publicado: (2017) -
Acquired Non-histaminergic Angioedema With C1q Autoantibody and Urticaria: A Case Report
por: Kochvar, Andrew P, et al.
Publicado: (2023) -
Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients
por: Dekkers, Coco, et al.
Publicado: (2021)